Alogliptin-d3

Alogliptin-d3 is the deuterium labeled Alogliptin. Alogliptin (SYR-322 free base) is a potent, selective and orally active inhibitor of DPP-4 with an IC50 of [1][2][3].

Product Specifications

CAS Number

[1133421-35-8]

Product Name Alternative

SYR-322-d3 (free base)

UNSPSC

12352005

Target

Dipeptidyl Peptidase; Ferroptosis; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Apoptosis; Metabolic Enzyme/Protease; Others

Field of Research

Metabolic Disease; Inflammation/Immunology; Cardiovascular Disease

Purity

99.61

Solubility

DMSO : 100mg/mL (ultrasonic) |H2O : 10mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C(N(C1=O)C([2H])([2H])[2H])C=C(N2C[C@@H](CCC2)N)N1CC3=C(C=CC=C3)C#N

Molecular Formula

C18H18D3N5O2

Molecular Weight

342.41

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216. |[2]Hao FL, et, al. The neurovascular protective effect of alogliptin in murine MCAO model and brain endothelial cells. Biomed Pharmacother. 2019 Jan;109:181-187.|[3]Feng J, et al. Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem. 2007 May 17;50 (10) :2297-300.|[4]Ta NN, et al. DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. Atherosclerosis. 2010 Dec;213 (2) :429-35.|[5]Asakawa T, et al. A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci. 2009 Jul 17;85 (3-4) :122-6.|[6]Moritoh Y, et al. The dipeptidyl peptidase-4 inhibitor alogliptin in combination with pioglitazone improves glycemic control, lipid profiles, and increases pancreatic insulin content in ob/ob mice. Eur J Pharmacol. 2009 Jan 14;602 (2-3) :448-54.